NATURAL ALTERNATIVES INTERNATIONAL (NAII) Company Report

Natural Alternatives International, Inc. (NAII) entered into a Waiver and Release Agreement with Wells Fargo Bank, National Association on December 17, 2025, to address non-compliance with its Credit Agreement.
For the fiscal first quarter ended September 30, 2025, NAII failed to maintain a net loss after taxes of not more than $250,000 and a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0.
Wells Fargo waived these defaults, allowing the Credit Agreement and related agreements to remain in full force and effect.
As part of the agreement, NAII reimbursed Wells Fargo's legal fees and paid a $10,000 waiver fee.

Dec 17, 2025, 10:13 PM

Natural Alternatives International Announces Q1 2026 Results

NAII

Earnings

Guidance Update

Revenue Acceleration/Inflection

For the first quarter of fiscal year 2026, Natural Alternatives International, Inc. reported net sales of $37.7 million and a net loss of $0.3 million, or $0.05 per diluted share, an improvement from a net loss of $2.0 million, or $0.33 per diluted share, in the prior year's comparable quarter.
Net sales increased by 13.8% year-over-year, primarily driven by a 17.7% increase in private-label contract manufacturing sales. CarnoSyn® beta-alanine royalty, licensing, and raw material sales revenue decreased by 33.9% to $1.7 million.
The company achieved income from operations in Q1 FY2026, contrasting with a loss from operations in Q1 FY2025, attributed to increased sales, improved gross profit, and relatively flat selling, general, and administrative expenses.
As of September 30, 2025, cash was $7.7 million and working capital was $31.2 million.
Management projects a net loss in the first half of fiscal 2026, but anticipates achieving net income in the second half and for the full fiscal 2026 year.

Nov 12, 2025, 9:44 PM

Get instant answers from SEC filings, earnings calls & more